Speier Discusses FDA and mHealth Utilization with Applied Clinical Trials


With the growth and increasing applications of mHealth come the need to regulate, and the biopharmaceutical industry and regulatory bodies such as the FDA are coming together to develop frameworks for mHealth utilization in clinical trials. Austin Speier, VP of Emerging Technologies at Precision for Medicine, spoke recently about mHealth regulatory pathways at PanAgora’s Mobile Innovations Summit; read the full article here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.